Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.